How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,067 results for

Thromboembolic Disease in Pregnancy

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Physical Activity in Pregnancy

of hypertensive disorders in pregnancy). Condition or disease Pregnancy, Physical Activity Detailed Description: Pregnancy is a natural state of low grade inflammation in the mother and the feto-placental unit. The severity of this inflammation increases with higher pregravid Body Mass Index (BMI). This is reflected by an increase in pro-inflammatory cytokines in the maternal circulation and in the placenta. It has been proposed that the pro-inflammatory maternal and fetal environment plays a role (...) ) Inactive pregnant women who are physically inactive (spend less than 150min/week with moderate to vigorous physical activity) risk for hypertensive disorders pregnant women with a history of preeclampsia or positive history for metabolic conditions increasing the risk of hypertensive disorders in pregnancy Outcome Measures Go to Primary Outcome Measures : low grade inflammation (in maternal and cord blood) [ Time Frame: 1 year ] clinical inflammation markers: C-reactive protein, cytokines and chemokine

2017 Clinical Trials

142. Autoimmune hepatitis and pregnancy: report of two cases with different maternal outcomes Full Text available with Trip Pro

Autoimmune hepatitis and pregnancy: report of two cases with different maternal outcomes Women of childbearing age with autoimmune hepatitis (AIH) are now able to get pregnant. The progress of the disease during pregnancy is not well clarified yet. The first pregnant woman had cirrhosis secondary to AIH, and she delivered by cesarean section. The patient had severe thrombocytopenia at the time of hospitalization. Unfortunately, she died due to massive thromboembolism at the 24th hour after (...) delivery. The other patient had three recurrent abortions with a diagnosis of AIH. Low-dose low molecular weight heparin and low-dose acetylsalicylic acid along with low-dose prednisolone were administered during the course of the following pregnancies. The following pregnancies ended up with a living child. There is a high morbidity and mortality risk for both fetus and mother. Hepatic performance of the patients, thrombotic events, inflammatory disorders and autoimmune system activation must

2017 Clinical and Experimental Hepatology

143. The Role of Prothrombin Gene Polymorphism as a Risk Factor for Recurrent Pregnancy Loss

Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies. Condition or disease Intervention/treatment Recurrent Pregnancy Loss Diagnostic Test: polymerase chain reaction Detailed Description: Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full (...) reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies. Thrombophilia is the tendency to develop thromboses due to inherited defects in the coagulation system. Thrombophilia was identified as a major cause of recurrent pregnancy loss , Because pregnancy is a hypercoagulable state, thromboembolism is the leading cause

2017 Clinical Trials

144. Pregnancy and reproductive aspects of systemic lupus erythematosus. (Abstract)

Pregnancy and reproductive aspects of systemic lupus erythematosus. To discuss pregnancy and reproductive aspects in women with systemic lupus erythematosus (SLE) with particular focus on preconception counselling, maternal and foetal outcomes, safety and beneficial effects of drugs during pregnancy as well as contraception methods, assisted reproduction techniques and strategies for thromboembolism prophylaxis in patients with positive antiphospholipid antibodies.Evidence-based recommendations (...) and risk stratification (based on disease activity and serological profile) are key points for having successful pregnancies thanks to individualized treatments and close monitoring for maternal and foetal complications. Contraception and assisted reproduction techniques are feasible in women with SLE, provided that potential risks are minimized by individualized management and appropriate prophylaxis.

2017 Current Opinion in Rheumatology

145. Obstetrical history of women with cerebral vein thrombosis: outcome of the pregnancies before and after the thrombotic event. (Abstract)

Obstetrical history of women with cerebral vein thrombosis: outcome of the pregnancies before and after the thrombotic event. Cerebral vein thrombosis (CVT) is a rare disease usually affecting young people, especially women, with a high prevalence of thrombophilic defects. It is known that thrombophilia is associated with pregnancy complications; therefore, a high rate of complications could be expected in women with the previous CVT who become pregnant. This study examined the whole obstetric (...) at prophylactic dosage during pregnancy. No recurrent CVT, venous thromboembolic events, or death was recorded during the observed pregnancies. Ten miscarriages were recorded (rate 8.1%), with a rate similar to that expected in the general population. We confirm the favorable outcome of pregnancies in women who suffered from CVT during their entire lifespan, whether they have occurred before and after or in relation to CVT.

2017 Internal and emergency medicine

146. Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills

, this risk is still very low and is much lower than the risk of venous thromboembolism during pregnancy and the immediate postpartum period. When prescribing any oral contraceptive, clinicians should consider a woman’s risk factors for venous thromboembolism and refer to the U.S. Medical Eligibility Criteria for Contraceptive Use issued by the Centers for Disease Control and Prevention. Patient education materials, including product labeling, should place information regarding oral contraceptive use (...) to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Risk of Venous Thromboembolism Among Users of Drospirenone-Containing Oral Contraceptive Pills ABSTRACT: Although the risk of venous thromboembolism is increased among oral contraceptive users compared with nonusers who are not pregnant and not taking hormones, and some data have suggested that use of drospirenone-containing pills has a higher risk of venous thromboembolism

2012 American College of Obstetricians and Gynecologists

147. Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast.

and Critical Care Institution: Lancashire Teaching Hospitals NHS Trust Date Submitted: 5th July 2011 Date Completed: 13th June 2012 Last Modified: 13th June 2012 Status: Green (complete) Three Part Question In [patients with lower extremity injury requiring temporary immobilisation with above knee plaster of paris] does [prophylactic anticoagulation with LMWH] reduce the risk of [venous thromboembolic disease within the next three months] Clinical Scenario You see a 27 year old male who has ruptured his (...) Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. BestBets: Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. Thromboprophylaxis reduces venous thromboembolism rate in ambulatory patients immobilised in above knee plaster cast. Report By: Catherine Roberts - SpR in Emergency Medicine & Critical Care Search checked by Daniel Horner - StR in Emergency Medicine

2012 BestBETS

148. Haemorrhages and Thromboembolic Venous Disease of the Postpartum

Thromboembolism Venous Thromboembolism Postpartum Hemorrhage Pathologic Processes Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Obstetric Labor Complications Pregnancy Complications Puerperal Disorders Uterine Hemorrhage (...) : University Hospital, Brest Information provided by (Responsible Party): University Hospital, Brest Study Details Study Description Go to Brief Summary: The aim of this study is to evaluate the frequencey and the determinants of postpartum major complications (hemorrhage and thrombosis) up to 3 months after delivery in the maternity hospitals of Finistère (Bretagne - France) Condition or disease Postpartum Hemorrhage Venous Thromboembolism Detailed Description: This is an analytical observational

2015 Clinical Trials

149. Is Infection an Independent Risk Factor for Venous Thromboembolism? a Population-Based Case-Control Study. Full Text available with Trip Pro

Olmsted County, Minnesota, residents with objectively diagnosed incident deep vein thrombosis or pulmonary embolism over the 13-year period 1988 to 2000 (cases; n = 1303) and 1 to 2 residents without venous thromboembolism matched to each case on age, sex, and incident venous thromboembolism date (controls; n = 1494). Using conditional logistic regression, we tested recent infection and infection site(s) for an association with venous thromboembolism, adjusting for body mass index, smoking, current (...) /recent hospitalization with/without surgery, nursing home confinement, active cancer, trauma/fracture, leg paresis, prior superficial vein thrombosis, transvenous catheter/pacemaker, ischemic heart disease, congestive heart failure, chronic lung or renal disease, serious liver disease, asthma, diabetes mellitus, hormone therapy, and pregnancy/postpartum.A total of 513 cases (39.4%) and 189 controls (12.7%) had an infection in the previous 92 days (odds ratio, 4.5; 95% confidence interval, 3.6-5.5; P

2017 American Journal of Medicine

150. Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region

: Recruiting First Posted : November 21, 2017 Last Update Posted : November 21, 2017 See Sponsor: Novosibirsk Scientific Research Institute for Circulatory Pathology Information provided by (Responsible Party): Novosibirsk Scientific Research Institute for Circulatory Pathology Study Details Study Description Go to Brief Summary: There will be assessment of patients after acute pulmonary embolism for the development of CTEPH Condition or disease Intervention/treatment Chronic Thromboembolic Pulmonary (...) Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2017 Clinical Trials

151. A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism

dose of dabigatran will be given within 2 hours before the time that the next dose of tinzaparin would have been due. Anticoagulation will be continued as long as malignancy is active. If patients achieve a complete remission of their underlying malignancies, dabigatran will be continued for 6 months further. Condition or disease Intervention/treatment Phase Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism Drug: Dabigatran etexilate Drug: Tinzaparin Phase 3 Detailed Description (...) Verified: October 2017 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: Undecided Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Additional relevant MeSH terms: Layout table for MeSH terms Thrombosis Thromboembolism Embolism Venous Thromboembolism Pulmonary Embolism Venous Thrombosis Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

2017 Clinical Trials

152. Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology

. Data comparing these two methods of VTE prophylaxis in patients undergoing pelvic/lower extremity orthopaedic surgery for malignancy are lacking, however, as compared to the data and guidelines present for VTE chemoprophylaxis after joint arthroplasty and hip fracture surgery. In this clinical trial, our specific aim is to compare the post operative incidence of VTE between patients receiving aspirin and LMWH after pelvic/lower extremity orthopaedic oncology procedures. Condition or disease (...) : 1) soft tissue sarcoma; 2) primary bone sarcoma; 3) metastatic bone disease. Within each of these groups, patients will be randomized to either aspirin or low molecular weight heparin (enoxaparin) for venous thromboembolism prophylaxis post operatively. Masking: None (Open Label) Primary Purpose: Prevention Official Title: Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology Actual Study Start Date : February 16, 2018 Estimated Primary

2017 Clinical Trials

153. REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.

, a reduced dose of DOAC will be non-inferior to a full dose of DOAC in terms of recurrent VTE during extended anticoagulation phase. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Reduced dose of DOAC Drug: Full dose of DOAC Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 2200 participants Allocation: Randomized Intervention Model: Parallel Assignment Intervention Model Description: The trial (...) Chronic liver disease or chronic hepatitis Patient considered at high risk of bleeding (eg: previous gastro-intestinal tract bleeding in the past three months, uncontrolled hypertension, etc.) Renal insufficiency with creatinine <25 ml / min on Cockcroft and Gault formula Antiphospholipid syndrome Dual anti-platelet therapy or aspirin at dosage >100 mg per day Concomitant use of a strong inhibitor of cytochrome P-450 3A4 (CYP3A4) (e.g., a protease inhibitor for human immunodeficiency virus infection

2017 Clinical Trials

154. Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

and rivaroxaban for the treatment of VTE. Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Rivaroxaban Phase 4 Detailed Description: VTE is the third leading cause of mortality by cardiovascular disease. Standard treatment for acute VTE uses a combination of parenteral Low-Molecular-Weight Heparin (LMWH) and oral vitamin K antagonists (VKA) for 3 months, and carries significant bleeding risk. The major and/or clinically-relevant non-major bleeding (CRNMB) event (...) ) pregnant (note below) or breastfeeding (Note: as reported by the patient or a pregnancy test will be ordered at the discretion of the treating physician for women of childbearing potential as per standard of care) Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT

2017 Clinical Trials

155. Distribution of Risk Factors for Venous Thromboembolism in Blood Donors

in patients with VTE. Condition or disease Intervention/treatment Venous Thromboembolism Risk Factor, Cardiovascular Blood Type Behavioral: no intervention Detailed Description: Venous thromboembolism, defined by deep vein thrombosis (DVT) and / or pulmonary embolism (PE), occurs with an incidence of about 1 per 1000 per year in adult populations. Rates are slightly higher in men than women. About two-thirds of the episodes are manifested as DVT and one third as PE with or without DVT. The main (...) of Bari Information provided by (Responsible Party): Elvira Grandone, MD, Head of Unit, Casa Sollievo della Sofferenza IRCCS Study Details Study Description Go to Brief Summary: Venous thromboembolism occurs with an incidence of about 1 per 1000 per year in adults . The main consequences are death, recurrence, post-thrombotic syndrome and major bleeding due to anticoagulation. Mortality rates are lower among patients with idiopathic venous thrombosis and higher among those in whom thrombosis occurs

2017 Clinical Trials

156. Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism

of bleeding or VTE recurrence. Condition or disease Intervention/treatment Venous Thromboembolism Drug: Apixaban Study Design Go to Layout table for study information Study Type : Observational Estimated Enrollment : 850 participants Observational Model: Cohort Time Perspective: Prospective Official Title: Monotherapy Anticoagulation To Expedite Home Treatment of Venous Actual Study Start Date : August 4, 2017 Estimated Primary Completion Date : December 31, 2020 Estimated Study Completion Date : December (...) or social reasons to admit Creatinine clearance >30mL/min Not pregnant, severe liver disease or heparin induced thrombocytopenia OR B. The physician opinion that a patients' overall social and medical situation is favorable for home treatment and the patient has a zero score on the simplified pulmonary embolism severity index (sPESI). All of the following must true: Age < 81 years No history of cancer No history of heart failure or chronic lung disease Pulse < 110 beats/min SBP > 99 mm Hg O2 sat >89

2017 Clinical Trials

157. Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer

Posted : October 26, 2018 See Sponsor: Fadoi Foundation, Italy Collaborator: University of Perugia, Italy Information provided by (Responsible Party): Fadoi Foundation, Italy Study Details Study Description Go to Brief Summary: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study Condition or disease Intervention/treatment Phase Venous Thromboembolism Drug: Apixaban Drug: Dalteparin Phase 3 Study Design Go (...) participation in other pharmaco therapeutic program with an experimental therapy that is known to effect the coagulation system; childbearing potential without proper contraceptive measures, pregnancy, or breast feeding; any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study

2017 Clinical Trials

158. Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

lung cancer and elevated D-dimer. Condition or disease Intervention/treatment Phase Venous Thromboembolism Lung Neoplasm Drug: Tinzaparin Sodium Phase 3 Detailed Description: Adult patients aged ≥ 18 years with stage IV lung cancer and elevated D-dimer will be randomized to the experimental or control group.Patients in the control group will receive usual care, patients in the experimental group will receive subcutaneous tinzaparin once daily for six months. Follow-up visit will take place (...) table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Assistance Publique - Hôpitaux de Paris: Low-molecular-weight Heparin Tinzaparin Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Venous Thromboembolism Lung Neoplasms Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases

2017 Clinical Trials

159. Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection

Update Posted : December 20, 2018 See Sponsor: McMaster University Information provided by (Responsible Party): McMaster University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine the incidence of post-operative venous thromboembolism (VTE) in patients undergoing major esophageal resection for malignancy. Condition or disease Venous Thromboembolism Thoracic Surgery Esophageal Cancer Detailed Description: Venous Thromboembolism (VTE) is a common post (...) therapies. Patients must receive VTE prophylaxis as per local institutional guidelines Patients must be competent to understand and sign consent documents. Exclusion Criteria: All patients with known allergic or anaphylactic reaction to contrast dye, heparin, or low molecular weight heparin (LMWH). Patients must not be under current anticoagulation for venous thromboembolism or other medical conditions. Patients must not have known renal impairment, defined as creatinine clearance value of less than

2017 Clinical Trials

160. Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events

participants will be enrolled under the same criteria and study procedures as Cohort 1. The participants in Cohort 2 will have the addition of Bilevel Positive Airway Pressure (BiPAP) during the 4DCT imaging. Cohort 3: 124 participants will be enrolled. Study procedure will be 4DCT only. Participants must be having or have had a CTA to rule out PE. This cohort of the study will be using 4DCT to compare negative CTA to positive CTA findings. Condition or disease Intervention/treatment Phase Pulmonary (...) a U.S. FDA-regulated Device Product: Yes Device Product Not Approved or Cleared by U.S. FDA: No Pediatric Postmarket Surveillance of a Device Product: No Product Manufactured in and Exported from the U.S.: No Additional relevant MeSH terms: Layout table for MeSH terms Thromboembolism Embolism Pulmonary Embolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>